Paolo Rebulla

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/996354/publications.pdf

Version: 2024-02-01

96 papers 4,517 citations

35 h-index 102487 66 g-index

103 all docs

103 docs citations

103 times ranked 5135 citing authors

#	Article	IF	Citations
1	Pathogen Reduction for Platelets—A Review of Recent Implementation Strategies. Pathogens, 2022, 11, 142.	2.8	5
2	Clinical evaluation of allogeneic eye drops from cord blood platelet lysate. Blood Transfusion, 2021, 19, 347-356.	0.4	8
3	A crosswalk tabular review on methods and outcomes from randomized clinical trials using pathogen reduced platelets. Transfusion, 2020, 60, 1267-1277.	1.6	10
4	The long and winding road to pathogen reduction of platelets, red blood cells and whole blood. British Journal of Haematology, 2019, 186, 655-667.	2.5	26
5	Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting. Blood Transfusion, 2019, 17, 433-448.	0.4	9
6	Ultraviolet lightâ€based pathogen inactivation and alloimmunization after platelet transfusion: results from a randomized trial. Transfusion, 2018, 58, 1210-1217.	1.6	23
7	Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 283-299.	1.6	217
8	Cord blood platelet gel treatment of dystrophic recessive epidermolysis bullosa. BMJ Case Reports, 2015, 2015, bcr2014207364-bcr2014207364.	0.5	18
9	Stem Cell Salvage of Injured Peripheral Nerve. Cell Transplantation, 2015, 24, 213-222.	2.5	17
10	Guidance on Platelet Transfusion for Patients With Hypoproliferative Thrombocytopenia. Transfusion Medicine Reviews, 2015, 29, 3-13.	2.0	87
11	Mononuclear cells from a rare blood donor, after freezing under good manufacturing practice conditions, generate red blood cells that recapitulate the rare blood phenotype. Transfusion, 2014, 54, 1059-1070.	1.6	15
12	Utility of crossâ€matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion, 2014, 54, 1180-1191.	1.6	35
13	Training practices of hematopoietic progenitor cell-apheresis and -cord blood collection staff: analysis of a survey by the Alliance for Harmonisation of Cellular Therapy Accreditation. Transfusion, 2014, 54, 3138-3144.	1.6	6
14	Evaluation of an easy and affordable flow cytometer for volumetric haematopoietic stem cell counting. Blood Transfusion, 2014, 12, 416-20.	0.4	8
15	Pleural tissue repair with cord blood platelet gel. Blood Transfusion, 2014, 12 Suppl 1, s235-42.	0.4	3
16	The Lombardy Rare Donor Programme. Blood Transfusion, 2014, 12 Suppl 1, s249-55.	0.4	5
17	Adipogenic potential in human mesenchymal stem cells strictly depends on adult or foetal tissue harvest. International Journal of Biochemistry and Cell Biology, 2013, 45, 2456-2466.	2.8	37
18	Allogeneic mesenchymal stem cell infusion for the stabilization ofÂfocal segmental glomerulosclerosis. Biologicals, 2013, 41, 439-445.	1.4	27

#	Article	IF	CITATIONS
19	What is beyond a q <scp>RT</scp> â€ <scp>PCR</scp> study on mesenchymal stem cell differentiation properties: how to choose the most reliable housekeeping genes. Journal of Cellular and Molecular Medicine, 2013, 17, 168-180.	3.6	128
20	Differential microRNA signature of human mesenchymal stem cells from different sources reveals an "environmental-niche memory―for bone marrow stem cells. Experimental Cell Research, 2013, 319, 1562-1574.	2.6	45
21	REXIC project: retrospective cross-sectional study of documentation of informed consent for research biobanking in a public research and teaching hospital. Journal of Public Health Research, 2013, 2, 10.	1.2	1
22	Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. Liver International, 2013, 33, 362-367.	3.9	107
23	Efficacy of <scp>HLA</scp> â€matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion, 2013, 53, 2230-2242.	1.6	40
24	A novel method for banking dental pulp stem cells. Transfusion and Apheresis Science, 2012, 47, 199-206.	1.0	51
25	From pH to MALDI-TOF: Hundreds of spotted opportunities?. Journal of Proteomics, 2012, 76, 270-274.	2.4	2
26	InÂVitro Evaluation of Graft-versus-Graft Alloreactivity as a Tool to Identify the Predominant Cord Blood Unit before Double Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1108-1118.	2.0	17
27	Identification of New Hematopoietic Cell Subsets with a Polyclonal Antibody Library Specific for Neglected Proteins. PLoS ONE, 2012, 7, e34395.	2.5	1
28	Role of the blood service in cellular therapy. Biologicals, 2012, 40, 218-221.	1.4	2
29	Human umbilical cord blood mesenchymal stem cells protect mice brain after trauma*. Critical Care Medicine, 2011, 39, 2501-2510.	0.9	130
30	Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial. Journal of Cardiovascular Medicine, 2011, 12, 239-248.	1.5	45
31	Banking cord blood stem cells: attitude and knowledge of pregnant women in five European countries. Transfusion, 2011, 51, 578-586.	1.6	39
32	Differentiation and migration properties of human foetal umbilical cord perivascular cells: potential for lung repair. Journal of Cellular and Molecular Medicine, 2011, 15, 796-808.	3.6	60
33	Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e21369.	2.5	56
34	Simultaneous characterization of progenitor cell compartments in adult human liver. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 31-40.	1.5	8
35	Life-Sparing Effect of Human Cord Blood-Mesenchymal Stem Cells in Experimental Acute Kidney Injury. Stem Cells, 2010, 28, 513-522.	3.2	161
36	A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion, 2010, 50, 2362-2375.	1.6	148

#	Article	IF	CITATIONS
37	The Role of PET with ¹³ N-Ammonia and ¹⁸ F-FDG in the Assessment of Myocardial Perfusion and Metabolism in Patients with Recent AMI and Intracoronary Stem Cell Injection. Journal of Nuclear Medicine, 2010, 51, 1908-1916.	5.0	38
38	Platelet gel from cord blood: A novel tool for tissue engineering. Platelets, 2010, 21, 549-554.	2.3	52
39	An analysis of decision making in cord blood donation through a participatory approach. Transfusion and Apheresis Science, 2010, 42, 299-305.	1.0	14
40	Cord blood banking and transplantation in 2010. Transfusion and Apheresis Science, 2010, 42, 253-254.	1.0	2
41	Stem cell and cellular therapy developments. Biologicals, 2009, 37, 103-107.	1.4	14
42	Cell Lines Derived from Human Parthenogenetic Embryos Can Display Aberrant Centriole Distribution and Altered Expression Levels of Mitotic Spindle Check-point Transcripts. Stem Cell Reviews and Reports, 2009, 5, 340-352.	5.6	40
43	Tenâ€year quality control of a semiautomated procedure of cord blood unit volume reduction. Transfusion, 2009, 49, 563-569.	1.6	11
44	Banking together. EMBO Reports, 2008, 9, 307-313.	4.5	88
45	Building and managing a biological resource centre. ISBT Science Series, 2008, 3, 119-123.	1.1	1
46	Development of a biological resource center for cellular therapy and biobanking in a public polyclinic university hospital. Biologicals, 2008, 36, 79-87.	1.4	10
47	Potential advantages of cell administration on the inflammatory response compared to standard ACE inhibitor treatment in experimental myocardial infarction. Journal of Translational Medicine, 2008, 6, 30.	4.4	14
48	Molecular and phenotypical characterization of human amniotic fluid cells and their differentiation potential. Bio-Medical Materials and Engineering, 2008, 18, 183-185.	0.6	3
49	Platelet transfusions. Lancet, The, 2007, 370, 427-438.	13.7	276
50	Oct-4 Expression in Adult Human Differentiated Cells Challenges Its Role as a Pure Stem Cell Marker. Stem Cells, 2007, 25, 1675-1680.	3.2	151
51	Biobanking in the Year 2007. Transfusion Medicine and Hemotherapy, 2007, 34, 286-292.	1.6	21
52	Development of a mock hemopoietic stem cell component suitable for the validation of cryopreservation procedures. Transfusion and Apheresis Science, 2006, 34, 299-307.	1.0	6
53	A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion, 2006, 46, 903-911.	1.6	45
54	Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential. Cell Research, 2006, 16, 329-336.	12.0	175

#	Article	IF	CITATIONS
55	Serial Transplantations in Nonobese Diabetic/Severe Combined Immunodeficiency Mice of Transduced Human CD34+Cord Blood Cells: Efficient Oncoretroviral Gene Transfer and Ex Vivo Expansion Under Serum-Free Conditions. Stem Cells, 2006, 24, 1201-1212.	3.2	8
56	Endothelial Colony Forming Capacity is Related to C-Reactive Protein Levels in Healthy Subjects. Current Neurovascular Research, 2006, 3, 99-106.	1.1	23
57	The Ethics of Cord Blood Banking in Light of Ownership, Informed Consent, and Solidarity. Cell Preservation Technology, 2006, 4, 91-96.	0.6	10
58	Biological Resource Centers, Cord Blood Banking, and Regenerative and Personalized Medicine. Cell Preservation Technology, 2006, 4, 2-3.	0.6	0
59	Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. British Journal of Haematology, 2004, 125, 83-89.	2.5	31
60	The translocation of marrow MNCs after experimental myocardial cryoinjury is proportional to the infarcted area. Transfusion, 2004, 44, 239-244.	1.6	4
61	Immune hemolytic anemia associated with teicoplanin. Transfusion, 2004, 44, 73-76.	1.6	16
62	Flow-cytometric approach to the prompt laboratory diagnosis of TRALI: a case report. European Journal of Haematology, 2004, 73, 295-299.	2.2	8
63	Review of the quality monitoring methods used by countries using or implementing universal leukoreduction. Transfusion Medicine Reviews, 2004, 18, 25-35.	2.0	21
64	Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice. Experimental Hematology, 2004, 32, 397-407.	0.4	384
65	Identification of preleukemic precursors of hyperdiploid acute lymphoblastic leukemia in cord blood. Genes Chromosomes and Cancer, 2004, 40, 38-43.	2.8	78
66	Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion, 2003, 43, 742-752.	1.6	85
67	The above letter was sent to Heddle et al.: Dr Heddle offered the following reply. Transfusion, 2003, 43, 1763-1763.	1.6	0
68	Correlation Between Perioperative Blood Transfusion and Prognosis of Patients Subjected to Surgery for Stage I Lung Cancer. Chest, 2003, 124, 102-107.	0.8	54
69	Cord blood banking 2002: 112,010 of 7,914,773 chances. Transfusion, 2002, 42, 1246-1248.	1.6	19
70	Peripheral blood count abnormalities among patients with hepatitis C in the United States. Hepatology, 2002, 36, 1025-1026.	7.3	2
71	Current status of cord blood banking and transplantation in the United States and Europe. Biology of Blood and Marrow Transplantation, 2001, 7, 635-645.	2.0	69
72	Long-term expansion and maintenance of cord blood haematopoietic stem cells using thrombopoietin, Flt3-ligand, interleukin (IL)-6 and IL-11 in a serum-free and stroma-free culture system. British Journal of Haematology, 2001, 112, 397-404.	2.5	42

#	Article	IF	CITATIONS
73	Outcomes of a program to evaluate mother and baby 6 months after umbilical cord blood donation. Transfusion, 2001, 41, 606-610.	1.6	12
74	Comparison of different serum-free media for ex vivo expansion of HPCs from cord blood using thrombopoietin, Flt-3 ligand, IL-6, and IL-11. Transfusion, 2001, 41, 718-719.	1.6	15
75	REVISITATION OF THE CLINICAL INDICATIONS FOR THE TRANSFUSION OF PLATELET CONCENTRATES. Reviews in Clinical and Experimental Hematology, 2001, 5, 288-310.	0.1	23
76	Ultrastructural Features of CD34+Hematopoietic Progenitor Cells from Bone Marrow, Peripheral Blood and Umbilical Cord Blood. Leukemia and Lymphoma, 2001, 42, 699-708.	1.3	11
77	Reasons for discard of umbilical cord blood units before cryopreservation. Transfusion, 2000, 40, 122-123.	1.6	25
78	In vitro quantification of anti-red blood cell antibody production in idiopathic autoimmune haemolytic anaemia: effect of mitogen and cytokine stimulation. British Journal of Haematology, 2000, 111, 452-460.	2.5	50
79	Practical placental blood banking*. Transfusion Medicine Reviews, 1999, 13, 205-226.	2.0	31
80	The Use and Quality Control of Leukocyte-Depleted Cell Concentrates. Vox Sanguinis, 1998, 75, 86-87.	1.5	0
81	Implementation of a Quality System (ISO 9000 Series) for Placental Blood Banking. Stem Cells and Development, 1998, 7, 19-35.	1.0	20
82	The Threshold for Prophylactic Platelet Transfusions in Adults with Acute Myeloid Leukemia. New England Journal of Medicine, 1997, 337, 1870-1875.	27.0	564
83	The sickle cell hemolytic transfusion reaction syndrome. Transfusion, 1997, 37, 1098-1099.	1.6	25
84	The Milan Cord Blood Bank and the Italian Cord Blood Network. Stem Cells and Development, 1996, 5, 117-122.	1.0	41
85	More on the safety of cord blood collection. Transfusion, 1996, 36, 937-938.	1.6	1
86	An improved method for white cell counting in white cell-reduced red cells. Transfusion, 1994, 34, 453-454.	1.6	11
87	Dose of desferrioxamine and evolution of HIV†infection in thalassaemic patients. British Journal of Haematology, 1994, 87, 849-852.	2.5	49
88	A bioassay of thyrotrophin by photografted mammalian cells onto polymeric supports. Biotechnology and Bioengineering, 1993, 42, 255-259.	3.3	2
89	HIV and HTLV infections in 1305 transfusion-dependent thalassemics in Italy. Aids, 1992, 6, 505-508.	2.2	26
90	DURATION OF FIRST REMISSION IN LEUKAEMIC RECIPIENTS OF LEUCOCYTEâ€POOR BLOOD COMPONENTS. British Journal of Haematology, 1992, 80, 135-135.	2.5	2

PAOLO REBULLA

#	Article	IF	CITATIONS
91	Incidence of AIDS in HIV-1 infected thalassaemia patients. British Journal of Haematology, 1992, 81, 109-112.	2.5	10
92	Removal of white cells from red cells by transfusion through a new filter. Transfusion, 1990, 30, 30-33.	1.6	71
93	The pH value in platelet concentrates prepared and stored for 5 days in bags of seven manufacturers. Transfusion, 1990, 30, 850-851.	1.6	2
94	Leukocyte contamination of platelet-rich plasma prepared using an optical sensor. Transfusion, 1987, 27, 368-368.	1.6	0
95	Red cell alloantibodies in thalassemia major. Results of an Italian cooperative study. Transfusion, 1985, 25, 110-112.	1.6	101
96	A new mutant erythrocyte glucosephosphate isomerase (GPI) associated with GSH abnormality. American Journal of Hematology, 1978, 5, 11-23.	4.1	13